In this month's newsletter, hear about the first hospitals to use CorPath GRX, learn about our new distribution agreement, and more.
Not rendering correctly? View this email as a web page here.
Corindus Announces First Commercial Procedures Performed Using CorPath® GRX System
We are pleased to announce that the first commercial procedures have been performed using the newly FDA cleared CorPath GRX System. In early February, NewYork-Presbyterian, UC San Diego Health, and University of Virginia Health System used CorPath GRX to perform robotic-assisted PCI procedures. "Completion of these initial CorPath GRX procedures marks an important step forward in vascular robotics," said Mark Toland, President and Chief Executive Officer of Corindus Vascular Robotics. "We are committed to continuing to develop and deliver innovative products to advance the field of cardiovascular robotics and support better patient outcomes."
Corindus Announces Strategic Distribution Partnership with MC Healthcare Group Granting Exclusive Rights to Distribute the CorPath® GRX System in Japan
We recently announced the signing of a strategic distribution agreement with Japan Medicalnext Co., Ltd., a wholly-owned entity of MC Healthcare, Inc. (subsidiary of Mitsubishi Corporation) and prominent supplier of medical devices in Japan. Pursuant to the agreement, Japan Medicalnext became the exclusive distributor of Corindus products in Japan and within 30 days will place an initial order for 12 CorPath GRX Systems. "We are pleased to be partnering with Corindus as the exclusive distributor of the CorPath GRX System in Japan," said Osamu Miyashita, CEO of MC Healthcare. "We have already received a very strong demand for robotic-assisted PCI from Japanese Key Opinion Leaders and the greater clinical community knowing that robotics has the potential to transform care for patients undergoing PCI procedures."
The Heart Hospital Baylor Plano Performs First Robotic-Assisted Angioplasty in Dallas Fort Worth
The Heart Hospital Baylor Plano recently announced the successful completion of the first robotic-assisted coronary angioplasty in the Dallas/Fort Worth region. The procedure has been performed using Corindus Vascular Robotics CorPath System—the first and only FDA-cleared medical device to bring robotic-assisted precision to coronary angioplasty procedures. “Combining the enhanced visualization of the X-ray images with robotic precision will transform the way we perform angioplasty procedures and should ultimately improve patient care,” said Srinivas Potluri, medical director of the cardiac catheterization laboratory at The Heart Hospital Baylor Plano.
Robots Rising: 4 Robotic Companies We All Foolishly Forgot About
In a recent LinkedIn post, Surgical Robotics NeuroMarketer Omar M. Khateeb discussed four robotics companies that are making an impact in medicine. Corindus is among the companies featured, citing both the protection afforded by the CorPath System and the implications for precision medicine as key factors that aim to set a new standard for PCI. The second generation CorPath GRX System is the next step towards redefining the cath lab with robotics.
CorPath 200 System is intended for use in the remote delivery and manipulation of coronary guidewires and balloon/stent catheters during PCI procedures
CorPath 200 System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventional procedures.
The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
Caution: Federal law restricts this device to sale by or on the order of a physician.
Copyright Corindus, Inc. 309 Waverley Oaks Road, Suite 105, Waltham, MA 02452, US Corporate Office: 508-653-3335 | Sales & Customer Service: 800-605-9635 | Fax: 508-232-6000